2. Search Result
Search Result
Results for "

Antinociception

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

3

Fluorescent Dye

4

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108068
    Alphadolone acetate

    Alfadolone acetate; GR 2/1574

    		 Others Neurological Disease
    Alphadolone acetate (Alfadolone acetate) is a steroid agent that can suppress or relieve pain, with antinociception .
    Alphadolone acetate
  • HY-110255
    AZD 2066
    1 Publications Verification

    		 mGluR Neurological Disease
    AZD 2066 is a selective, orally active and brain-penetrant antagonist of mGluR5. AZD 2066 has antinociception effects .
    AZD 2066
  • HY-12122A
    AR-C102222 hydrochloride

    		NO Synthase Neurological Disease Inflammation/Immunology
    AR-C102222 hydrochloride is a potent, competitive, orally active and highly selective inducible nitric oxide synthase (iNOS) inhibitor, with an IC50 of 37 nM . AR-C102222 hydrochloride has antinociception and anti-inflammatory activities .
    AR-C102222 hydrochloride
  • HY-W020183
    γ-Terpinene

    		Others Neurological Disease
    γ-Terpinene, a monoterpene, is an orally active antioxidant compound which can scavenge radicals directly. γ-Terpinene has potent antinociception activity .
    γ-Terpinene
  • HY-122135
    A-317567

    		Sodium Channel Neurological Disease
    A-317567 is a potent acid-sensing ion channel 3 (ASIC-3) inhibitor with an IC50 of 1.025 μM. A-317567 has antidepressant and antinociception effects .
    A-317567
  • HY-138885
    Tryptamine guanosine carbamate

    TpGc

    		 Others Neurological Disease
    Tryptamine guanosine carbamate (TpGc) is a selective HINT1 (histidine triad nucleotide-binding protein 1) inhibitor (Ki=34 μM, Kd=3.65 μM). Tryptamine guanosine carbamate significantly enhances morphine antinociception while preventing the development of tolerance .
    Tryptamine guanosine carbamate
  • HY-110255A
    AZD 2066 hydrate

    		mGluR Neurological Disease
    AZD 2066 hydrate is a selective, orally active and brain-penetrant antagonist of mGluR5. AZD 2066 hydrate has antinociception effects .
    AZD 2066 hydrate
  • HY-W020183R
    γ-Terpinene (Standard)

    		Others Neurological Disease
    γ-Terpinene (Standard) is the analytical standard of γ-Terpinene. This product is intended for research and analytical applications. γ-Terpinene, a monoterpene, is an orally active antioxidant compound which can scavenge radicals directly. γ-Terpinene has potent antinociception activity .
    γ-Terpinene (Standard)
  • HY-34439S1
    2,5-Dimethylpyrazine-d3

    NSC 49139-d3

    		 Endogenous Metabolite Isotope-Labeled Compounds Metabolic Disease
    2,5-Dimethylpyrazine-d3 is deuterated labeled γ-Terpinene (HY-W020183). γ-Terpinene, a monoterpene, is an orally active antioxidant compound which can scavenge radicals directly. γ-Terpinene has potent antinociception activity .
    2,5-Dimethylpyrazine-d3
  • HY-162728
    RO-76

    		Opioid Receptor Neurological Disease
    RO-76 is a mu opioid receptor (μOR) selective partial agonist. RO-76 binds to μOR-G-protein complex with an EC50 value of 454 nM. RO-76 reduces β-Arrestin-1/2 recruitment. RO-76 shows antinociception activity .
    RO-76
  • HY-119733
    BU09059

    		Opioid Receptor Neurological Disease
    BU09059 is a potent and selective Kappa-opioid receptor antagonist with a pA2 of 8.62. BU09059 has nanomolar affinity for the κ-receptor, with 15-fold and 616-fold selectivity over μ- and δ-receptors, respectively. BU09059 significantly blocks U50488 (HY-15997B)-induced antinociception .
    BU09059
  • HY-144738
    Dual FAAH/sEH-IN-1

    		Epoxide Hydrolase FAAH Inflammation/Immunology
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .
    Dual FAAH/sEH-IN-1
  • HY-130354
    Dibutyryl-cGMP sodium
    2 Publications Verification

    Bt2cGMP sodium

    		 Potassium Channel Cardiovascular Disease
    Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits the release of [ 3H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K + channels .
    Dibutyryl-cGMP sodium
  • HY-B1359
    Methylene blue trihydrate
    Maximum Cited Publications
    14 Publications Verification

    C.I. Basic Blue 9 trihydrate

    		 Guanylate Cyclase Monoamine Oxidase NO Synthase Parasite Infection Neurological Disease Cancer
    Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures. Methylene blue trihydrate has antinociception, antimalarial, antidepressant and anxiolytic activity effects. Methylene Blue trihydrate has the potential for methemoglobinemias, neurodegenerative disorders and ifosfamide-induced encephalopathytreatment .
    Methylene blue trihydrate
  • HY-139678
    SC13

    		Opioid Receptor Others
    SC13 is a novel mitragynine analog with low-efficacy Mu opioid receptor agonism that displays antinociception with attenuated adverse effects.
    SC13
  • HY-10487
    JDTic dihydrochloride

    		Opioid Receptor Neurological Disease
    JDTic (dihydrochloride) is a potent antagonist of kappa-opioid receptors (KOR), blocking the κ-agonist U50, 488-induced antinociception.
    JDTic dihydrochloride
  • HY-110014
    Noladin ether

    		Cannabinoid Receptor Neurological Disease
    Noladin ether is a potent and selective agonist of cannabinoid CB1 receptor, with a Ki of 21.2 nM. Noladin ether can cause hypothermia, intestinal immobility, and mild antinociception .
    Noladin ether
  • HY-101373A
    Zolantidine dimaleate

    SKF 95282 dimaleate

    		 Histamine Receptor Neurological Disease
    Zolantidine dimaleate (SKF 95282 dimaleate) is a potent, selective and cross the blood-brain barrier histamine H2 antagonist. Zolantidine dimaleate induces antinociception .
    Zolantidine dimaleate
  • HY-P1502
    β-Endorphin, human
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.
    β-Endorphin, human
  • HY-107561
    A-943931 hydrochloride

    		Others Inflammation/Immunology
    A-943931 (Compound 10) is a histamine H4 receptor antagonists. A-943931 has improved pharmacotropic and in vivo efficacy in models of pain and inflammation. A-943931 can be used in vivo anti-inflammatory and anti-nociception research .
    A-943931 hydrochloride
  • HY-103203
    ST91

    		Adrenergic Receptor Neurological Disease
    ST91 is a α2-adrenoceptor (α2AR) agonist. ST91 activates both α2AAR and non-α2AAR subtypes to produce spinal antinociception .
    ST91
  • HY-106199
    Adenosine A1 receptor activator T62
    1 Publications Verification

    		 Adenosine Receptor Neurological Disease Inflammation/Immunology
    Adenosine A1 receptor activator T62 is an allosteric enhancer of adenosine A1 receptor. Adenosine A1 receptor activator T62 produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain .
    Adenosine A1 receptor activator T62
  • HY-110094
    BIMU 8

    		5-HT Receptor Neurological Disease
    BIMU 8 is a potent and selective 5-HT4 agonist with EC50s of 18 nM, 77 nM, and 540 nM for wild type 5HT4 receptor, T3.36A, and W6.48A mutant 5-HT4 receptors .
    BIMU 8
  • HY-12717A
    Phentolamine hydrochloride
    3 Publications Verification

    		 Adrenergic Receptor Metabolic Disease
    Phentolamine hydrochloride is an orally active adrenergic α receptor-blocking agent .
    Phentolamine hydrochloride
  • HY-N7640
    Deoxylimonin

    		Others Inflammation/Immunology Cancer
    Desoxylimonin is an orally active triterpenoid compound found from grapefruit seed. Desoxylimonin shows anti-proliferative activities to breast cancer cells. Desoxylimonin derivatives shows better anticancer, analgesic and anti-inflammatory activity than the lead compound .
    Deoxylimonin
  • HY-134189A
    EST73502 monohydrochloride

    		Sigma Receptor Opioid Receptor Neurological Disease
    EST73502 monohydrochloride is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 monohydrochloride has antinociceptive activity .
    EST73502 monohydrochloride
  • HY-134189
    EST73502

    		Opioid Receptor Sigma Receptor Neurological Disease
    EST73502 is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 has antinociceptive activity .
    EST73502
  • HY-117040
    nor-Binaltorphimine
    4 Publications Verification

    Norbinaltorphimine; NorBNI

    		 Opioid Receptor Others
    nor-Binaltorphimine is a selective antagonist of kappa-opioid receptor. nor-Binaltorphimine has a long-lasting effect in vivo .
    nor-Binaltorphimine
  • HY-B0219
    Allopurinol
    5+ Cited Publications

    		 Xanthine Oxidase Infection Neurological Disease Inflammation/Immunology Cancer
    Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .
    Allopurinol
  • HY-B0219A
    Allopurinol sodium
    5+ Cited Publications

    		 Xanthine Oxidase Infection Neurological Disease Inflammation/Immunology Cancer
    Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .
    Allopurinol sodium
  • HY-11079
    A-803467
    2 Publications Verification

    		 Sodium Channel Neurological Disease Inflammation/Immunology
    A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .
    A-803467
  • HY-B0219R
    Allopurinol (Standard)

    		Xanthine Oxidase Infection Neurological Disease Inflammation/Immunology Cancer
    Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .
    Allopurinol (Standard)
  • HY-122681
    SR-16435

    		Opioid Receptor Neurological Disease
    SR-16435 is a nociceptin/orphanin FQ (NOP)/μ-opioid receptor partial agonist, with high binding affinity (NOP receptor Ki=7.49; μ-Opioid receptor Ki=2.70). SR-16435 can relieve pain .
    SR-16435
  • HY-14536
    Methylene Blue
    Maximum Cited Publications
    14 Publications Verification

    Basic Blue 9; CI-52015; Methylthioninium chloride

    		 Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin Infection Neurological Disease Cancer
    Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
    Methylene Blue
  • HY-101202
    SNC80

    NIH 10815

    		 Opioid Receptor Neurological Disease
    SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
    SNC80
  • HY-D0958
    Methylene blue hydrate
    Maximum Cited Publications
    14 Publications Verification

    Basic Blue 9 hydrate; CI-52015 hydrate; Methylthioninium chloride hydrate

    		 Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin Infection Inflammation/Immunology Cancer
    Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
    Methylene blue hydrate
  • HY-D0958R
    Methylene blue hydrate (Standard)

    		Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin Infection Inflammation/Immunology Cancer
    Methylene blue (hydrate) (Standard) is the analytical standard of Methylene blue (hydrate). This product is intended for research and analytical applications. Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
    Methylene blue hydrate (Standard)
  • HY-14536A
    Methylene blue (purity≥70%)

    Basic Blue 9 (purity≥70%); CI-52015 (purity≥70%); Methylthioninium chloride (purity≥70%)

    		 Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin Infection Neurological Disease Cancer
    Methylene blue (purity≥70%) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue (purity≥70%) is a vasopressor and is often used as a dye in several medical procedures. Methylene blue (purity≥70%) through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue (purity≥70%) is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue (purity≥70%) is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
    Methylene blue (purity≥70%)
  • HY-14536R
    Methylene Blue (Standard)

    		Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin Infection Neurological Disease Cancer
    Methylene Blue (Standard) is the analytical standard of Methylene Blue. This product is intended for research and analytical applications. Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
    Methylene Blue (Standard)
  • HY-P0185
    Endomorphin 1
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    Endomorphin 1, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .
    Endomorphin 1
  • HY-P0185A
    Endomorphin 1 acetate
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties .
    Endomorphin 1 acetate
  • HY-136208
    TAN-452

    		Opioid Receptor Neurological Disease
    TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .
    TAN-452

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: